The Effect of Omega-3 Supplement on Serum Lipid Profile in Patients Undergoing Hemodialysis: A Randomized Clinical Trial
|
|
- Poppy Bradley
- 6 years ago
- Views:
Transcription
1 The Effect of Omega-3 Supplement on Serum Lipid Profile in Patients Undergoing Hemodialysis: A Randomized Clinical Trial MOSADEGH JABBARI 1, TERMEH KHOSHNEVIS 2, ARIA JENABI 1, FATEMEH YOUSEFI 3 1 Nephrology Department, Rasoul-e-Akram Hospital, Iran University of Medical Science, Tehran, Iran 2 Internal Medicine Department, Rasoul-e-Akram Hospital, Iran University of Medical Science, Tehran, Iran 3 MA, Nutrition Department, Rasoul-e-Akram Hospital, Iran University of Medical Science, Tehran, Iran Background. Some recent suggestions could show omega-3 condition deficiency following prolonged hemodialysis; however, these claims and speculations have not been well demonstrated with sufficient evidences. Hence, we attempted to assess the beneficial effects of omega-3 on lipid profile in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Methods. One hundred and seventeen ESRD patients who were on maintenance dialysis in Rasoul-e-Akram and Madaen Hospitals were enrolled in this randomized clinical trial. These patients were divided into two groups randomly using block randomization method (57 patients as the case group receiving omega-3 for 12 weeks and 60 as the control group). Blood sample was taken from all patients for measurement of lipid profile, serum hemoglobin, and C-reactive protein at baseline as well as after the completion of interventions (after 12 weeks). Results. The average change in the value of HDL-C was significantly more in the patients who received omega-3 than in the control group (MD, -7 mg/dl; 95% CI, -11 to 0 p = 0.000). Also, the reduction in serum creatinine level was more in the omega-3 group than in the control group (MD, 0.7 mg/dl; 95% CI, -0.4 to 2.1 p = 0.023). The change in other indices including serum triglyceride, total cholesterol, and serum hemoglobin levels was not different between the two groups. The multivariable linear regression analysis showed no difference in serum HDL level between the two groups adjusted for sex, age, and time of dialysis, while the level of serum HDL-C could be adversely predicted by duration time. Similar regression model showed a between-group difference in serum creatinine in the presence of potential confounders. Conclusion. The change in serum HDL level following use of omega-3 supplement is influenced by time of dialysis, not by drug effect. However, consumption of omega-3 can significantly reduce serum creatinine. Key words: omega-3, supplementation, lipidprofile, hemodialysis. INTRODUCTION Hyperlipidemia is an important risk factor leading high mortality and morbidity in patients with chronic kidney disease. The baseline pathogenesis of lipid disturbances in dialysis conditions is first related to involve defective lipid removal especially triglyceride release alteration from the circulation probably due to reduction in the activity of hepatic triglyceride lipase [1-3]. Another pathogenesis was shown to be parathyroid dysfunction leading increase in calcium accumulation in adipose tissue and liver [4-5]. Some human and animalbased experiments have shown that parathyroidectomy or using calcium channel blockers, the normalization of serum lipid profile in dialysis patients can be achieved [6]. Moreover, it has been shown that the retention of the inhibitors of lipoprotein lipase such as Pre-beta-HDL may lead to hypertriglyceridemia [7]. All of these mechanisms can predispose the chronic kidney disease (CKD) patients to lipid profile disturbances and consequently to cardiovascular disorders. Therefore, applying lipid lowering agents can warrant preventing development of cardiovascular disorders and related adverse events in renal failure patients. Recent evidences have emphasized the valuable role of fish oil-derived bioactive fatty acids in preventing lipid profile disorders [8-10]. Fish oil and its useful derivatives such as omega-3 have well-defined preventive effects on cardiovascular adverse consequences by inhibiting coronary atherosclerosis as well as inflammatory processes [11-12]. Thus, supplying omega-3 by rich food components or by omega-3 ROM. J. INTERN. MED., 2016, 54, 4,
2 2 Omega-3 supplement in patients undergoing hemodialysis 223 supplementations can effectively prevent coronary artery disease progression or its underlying risk factors such as lipid disturbances. According to this fact that chronic kidney patients undergoing hemodialysis are considerably vulnerable to metabolic and hemodynamic changes, any change in lipid profile can result in unpleasant consequences that should be quickly prevented. Some recent suggestions could show omega-3 condition inadequacy following prolonged hemodialysis [13-14]; however, these claims and speculations have not been well demonstrated by sufficient evidences. Hence, we attempted in the present study to assess the beneficial effects of omega-3 on lipid profile in patients with endstage renal disease (ESRD) undergoing hemodialysis. MATERIALS AND METHODS One hundred and seventeen ESRD patients who were on maintenance dialysis in Rasoul-e- Akram and Madaen Hospitals were enrolled in this randomized clinical trial. These patients were divided into two groups randomly using block randomization method (57 patients as the case group receiving omega-3 and 60 patients as the control group). The exclusion criteria were consuming on other antilipid medications, a recent history of active infectious or inflammatory disease, abnormalities documented by liver function tests. All participants gave informed consent after the nature and intent of the study was fully explained to them. The research protocol was approved by the Ethics Committee of Iran University of Medical Sciences. In our experiment, the patients in the omega-3 group received one pill of omega-3 (1000 mg) with each meal for 12 weeks. Participants in the placebo group were assigned to use oral pills of placebo for the same time. Baseline characteristics, including demographics, anthropometric parameters, disease and dialysis duration and oral medications were collected by interview. Blood sample was taken from all patients for measurement of lipid profile, serum hemoglobin, serum creatinine and C-reactive protein at baseline as well as after the completion of interventions (after 12 weeks). Serum total cholesterol and triglyceride were measured by applying the enzymatic method and HDL and LDL particles by means of the homogeneous assay method using an automated analyzer. Serum hemoglobin was measured by cyanide methemoglobin method. For statistical analysis, results were presented as mean ± standard deviation (SD) for parametric quantitative variables and median (1 st, 3 rd quartiles) for nonparametric variables and were summarized by absolute frequencies and percentages for categorical variables. Normality of data was analyzed using the Kolmogorov-Smirnoff test. Categorical variables were compared using chi-square test or Fisher's exact test, when more than 20% of cells with expected count of less than 5 were observed. Quantitative variables were also compared with t test or Mann- Whitney U test. The change in study parameters after completing study interventions compared to baseline was assessed using the Paired t test or non-parametric Wilcoxon test. The multivariate linear regression model was also used to compare the change in parameters between the two study groups with the presence of baseline variables. For the statistical analysis, the statistical software SPSS version 16.0 for windows (SPSS Inc., Chicago, IL) was used. P values of 0.05 or less were considered statistically significant. RESULTS The details of baseline characteristics were primarily compared between the omega-3 group and control group. As shown in Table 1, the two groups were similar in terms of mean age, mean body mass index and prevalence of diabetes mellitus, whereas male to female ratio, prevalence of hypertension, and prevalence of polycystic kidney disease (PCKD) were significantly higher in those patients receiving omega-3 than in the control group. Comparing lipid profiles after interventions compared to the baseline (Table 2), the average increase in the value of HDL-C was significantly higher in the patients who received omega-3 than in the control group (MD, -7 mg/dl; 95% CI, -11 to 0 p = 0.000). Also, the reduction in serum creatinine level was more important in the omega-3 group than in the control group (MD, 0.7 mg/dl; 95% CI, -0.4 to 2.1 p = 0.023). The change in other indices including serum triglyceride, total cholesterol, and serum hemoglobin levels was not different between the two groups. We also showed that there was no difference in the mean duration of dialysis between omega-3 and control groups 24 (12,48) years versus 12 (7.25,36), p = 0.083). The multivariable linear regression analysis (Table 3) showed no difference in serum HDL level between the two
3 224 Mosadegh Jabbari et al. 3 groups adjusted for sex, age, and time of dialysis (p = 0.138), while the level of serum HDL-C could be adversely predicted by duration time. Similar regression model (Table 4) showed a betweengroup difference in serum creatinine in the presence of potential confounders. Table 1 Baseline characteristics between the omega-3 group and control group Characteristics Omega-3 group Control group P-value Male gender 42 (73.7%) 33 (55.0%) Age, years ± ± BMI, kg/m ± ± Hypertension 15 (26.3%) 30 (50.0%) Diabetes mellitus 33 (57.9%) 33 (55.0%) PCKD 9 (15.8%) 0 (0.0%) Table 2 The change in study parameters after intervention in the omega-3 group and control group Characteristics Omega-3 group Control group P-value Triglyceride -3 (-30,17) -3.5(-13.2,4.7) Total cholesterol -3(-21,10) -5(-15.5,6.5) LDL-C 4(-2,10) -2(-8,13) HDL-C -7(-11,0) 3(-9.5,7.5) Serum creatinine 0.7(-0.4,2.1) 0.4(-1,1.15) Serum hemoglobin -0.4(-2.3,-0.1) -0.95(-1.7,0.25) Table 3 Multivariate linear regression analysis to assess group difference in serum HDL level Standardized Unstandardized Coefficients Variable Coefficients t Sig. B Std. Error Beta (Constant) Group Sex Age Time* * duration of dialysis Table 4 Multivariate linear regression analysis to assess group difference in serum creatinine level Standardized Unstandardized Coefficients Variable Coefficients t Sig. B Std. Error Beta (Constant) Group Sex Age Time DISCUSSION The information that this study is the second largest study with omega-3 in hemodialysis patients. In parallel with the previous findings on beneficial effects of omega-3 supplying on lipid lowering in people who were predisposed to cardiovascular disorders especially patients with ESRD, our study aimed to assess the effects of consuming omega-3 on serum lipid profiles in patients undergoing hemodialysis. In this context, our study had two important findings. First, we could show that although serum HDL was more significantly changed in omega-3 group than in the control group, considering time of dialysis as an important baseline parameter showed that the level of serum HDL was more affected by this factor than by drug intervention. In other words, more change in serum HDL level was
4 4 Omega-3 supplement in patients undergoing hemodialysis 225 in line with prolonged dialysis in ESRD patients. As another important result, the level of serum creatinine was directly affected by using omega-3 supplement adjusted for other baseline indices factors such as time of dialysis. Reviewing the previous studies could also find similar results regarding beneficial effects of omega-3 on lipid profile. In a recent study by Omrani et al. [15], 10 weeks treatment with omega-3 leads to more lower total cholesterol but no other lipid particles such as serum HDL, LDL, or triglyceride levels. In another study by Taziki et al. and similar to ours [16], consumption of omega-3 supplement for 12 weeks led to reduction in serum HDL level without significant difference in other lipid profiles. Hassan et al. [17] also showed that the use of omega-3 for 8 weeks resulted in significantly reduced serum triglycerides, but without observable change in other lipid components such as cholesterol, LDL, or HDL. In fact, the consumption of omega-3 supplement with the different dosages for different treatment time might be accompanied with different effects on lipid profiles. Some studies could describe the mechanisms of the impact of omega-3 on lipid metabolism. It has been well shown that omega-3 fatty acids can decrease the synthesis and secretion of VLDL particles, and also increase TG removal from VLDL and chylomicron particles through the upregulation of enzymes, such as lipoprotein lipase [18]. As previously pointed, it seems that the effects of omega-3 on lipid profiles are completely dose dependent. In a review by Harris et al. [19], 4 g/day of omega-3 fatty acids from fish oil decreased serum triglyceride concentrations to 25-30%. There were accompanying increases in low density lipoprotein (LDL) cholesterol of 5-10%, in high density lipoprotein (HDL) cholesterol of 1-3% and a dose-response relationship between omega-3 fatty acid intake and triglyceride lowering. In total, the effects of omega-3 on lipid profiles such as HDL may be intensified by prolonged hemodialysis. In fact, as indicated in our study, the main mechanism for increase the level of HDL following omega-3 use may be affected by the time of dialysis, so prolonged dialysis can cause lower change in HDL level. As Lapuz et al. [20] showed an inverse correlation of total cholesterol and HDL levels with months on dialysis. Thus, the change in HDL is mainly associated with time of dialysis, but not with the mechanical effects of omega-3 on lipids. As another important result and in contrary to the effect of omega-3 on lipids, this supplement could effectively reduce serum creatinine, which is a remarkable finding. In a meta-analysis by Chi et al. [21] it was shown that Omega-3 supplementation could significantly decrease the levels of TG (MD, mg/dl; 95% CI, to -7.28) and LDL (MD, mg/dl; 95% CI, to -4.2). It was previously pointed in some similar studies. In an animal study by Ashtiyani et al. [22], the decrease in glomerular filtration rate induced by reperfusion was relatively improved by omega-3 administration, which resulted in the decrease in plasma urea and creatinine concentrations. The use of omega-3 might be also preventive for renal dysfunction. As indicated by Holm et al. [23], plasma creatinine increased and glomerular filtration rate decreased in the placebo group, while no changes were observed in the omega-3 group, for explaining the preventive effect of this drug on renal dysfunction. Therefore, the use of omega-3 supplement can effectively reduce serum creatinine that is very vital for CKD patients. CONCLUSIONS Using omega-3 supplement leads to increase in serum HDL concentration, however this significant change may be indirectly affected by time on dialysis, not directly by the effects of omega-3 on lipid metabolism. In this study, omega-3 significantly reduced serum creatinine, which could be an important therapeutic effect of this medication in ESRD patients undergoing dialysis. Conflict of interest. There is no conflict of interest. Acknowledgment. Authors wish to thank Rasoul-e-Akram Hospital, Clinical Research Development Center for technically supported implementation of the project. Introducere. Studii recente au arătat faptul că acizii graşi omega-3 ar avea beneficii la pacienţii cu hemodializă prelungită. Totuşi sunt necesare studii suplimentare care să aducă un nivel al evidenţei mai mare. Scopul studiului a fost de a evalua efectele benefice ale acizilor graşi omega-3 asupra profilului lipidic la pacienţii cu boală renală cronică în stadiul final (ESRD) ce sunt supuşi hemodializei.
5 226 Mosadegh Jabbari et al. 5 Materiale şi metode. 117 pacienţi ESRD din spitalele Rasoul e-akramsi Madaen au fost incluşi în acest studiu clinic randomizat. Aceştia au fost împărţiţi în două grupuri după ce a avut loc randomizarea în bloc (57 de pacienţi au primit omega-3 pentru 12 săptămâni şi 60 au constituit grupul martor). Au fost prelevate probe sanguine pentru analiza profilului lipidic, hemoglobinei, nivelurile proteinei C reactive atât la momentul înrolării, cât şi ulterior după finalizarea celor 12 luni. Rezultate. Valorile HDL-colesterolului au fost modificate mai mult în grupul cu omega-3 comparativ cu grupul martor (MD, -7 mg/dl; 95% CI, -11 la 0 p = 0.000). În plus, reducerea creatininei serice a fost mai importantă în grupul ce a primit tratament cu omega-3 comparativ cu grupul martor (MD, 0.7 mg/dl; 95% CI, -0.4 la 2.1 p = 0.023). Nu au fost diferenţe semnificative între modificările survenite la nivelul valorilor trigliceridelor serice, ale hemoglobinei sau ale colesterolului total. Analiza de regresie multivariată a arătat că nu este nicio diferenţă semnificativă statistic între nivelurile HDL colesterolului după ce s-a făcut ajustarea după sex, vârstă şi durata dializei. Un model similar de regresie a arătat faptul că există o diferenţă între valorile serice ale creatininei în prezenţa anumitor factori de confuzie. Concluzii. Modificările datorate HDL-colesterolului apar mai ales datorită duratei dializei şi nu a suplimentării cu omega-3 însă terapia cu omega-3 ar putea scădea semnificativ nivelurile creatininei serice. Correspondence to: TermehKhoshnevis, MD, Nephrology Department, Rasoul-e-Akram Hospital, Iran University of Medical Science, Tehran, Iran Tel: khoshnevis_med80@yahoo.com. REFERENCES 1. SENTÍM, ROMERO R, PEDRO-BOTET J, PELEGRÍA, NOGUÉS X, RUBIÉS-PRAT J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992; 41: ATTMAN PO, SAMUELSSON O, ALAUPOVIC P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21: ARNADOTTIR M, THYSELL H, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 1995; 48: LACOUR B, ROULLET JB, LIAGRE AM, JORGETTI V, BEYNE P, DUBOST C, DRÜEKE T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8: LIANG K, OVEISI F, VAZIRI ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998; 53: AKMAL M, PERKINS S, KASIM SE, OH HY, SMOGORZEWSKI M, MASSRY SG. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis. 1993; 22: CHEUNG AK, PARKER CJ, REN K, IVERIUS PH. Increased lipase inhibition in uremia: identification of pre-beta-hdl as a major inhibitor in normal and uremic plasma. Kidney Int. 1996; 49: KRIS-ETHERTON PM, HARRIS WS, APPEL LJ, et al. American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106: SERHAN CN, HONG S, GRONERT K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med.2002;196: HARRIS WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr. 1997; 65:1645S-1654S. 11. ERITSLAND J, ARNESEN H, GRONSETH K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996; 77: THIES F, GARRY JM, YAQOOB P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003; 361: FRIEDMAN AN, MOE SM, PERKINS SM, et al. Fish consumption and omega-3 fatty acid status and determinants in longterm hemodialysis. J Am Kidney Dis 2006: FRIEDMAN AN, SIDDIQUI R, WATKINS BA. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008; 18(3):301-3.
6 6 Omega-3 supplement in patients undergoing hemodialysis OMRANI HR, PASDAR Y, RAISI D, NAJAFI F, ESFANDIARI A. The effect of omega-3 on serum lipid profile in hemodialysis patients. J Renal Inj Prev. 2015; 4: TAZIKI O, LESSAN-PEZESHKI M, AKHA O, VASHEGHANI F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007; 18(4): HASSAN KS, HASSAN SK, HIJAZI EG, KHAZIM KO. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail. 2010; 32: BAYS HE, TIGHE AP, SADOVSKY R, DAVIDSON MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc. Ther. 2008; 6: HARRIS WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr 1997; 65:S LAPUZ M, AVRAM MM, LUSTIG A, GOLDWASSER P, ANTIGNANI A, FEIN PA, et al. Fall of cholesterol with time on dialysis: impact on atherogenicity. ASAIO Trans. 1989; 35: CHI H, LIN X, HUANG H, ZHENG X, LI T, ZOU Y. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014; 45: ASHTIYANI SC, NAJAFI H, KABIRINIA K, VAHEDI E, JAMEBOZORKYL. Oral omega-3 fatty acid for reduction of kidney dysfunction induced by reperfusion injury in rats. Iran J Kidney Dis. 2012; 6: HOLM T, ANDREASSEN AK, AUKRUST P, ANDERSEN K, GEIRAN OR, KJEKSHUS J, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 2001; 22: Received March 9, 2016
JMSCR Vol 07 Issue 01 Page January 2019
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.66 Lipid Profile in Different Stages
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationINTERNATIONAL JOURNAL OF BIOASSAYS ISSN: X CODEN: IJBNHY OPEN ACCESS
ORIGINAL RESEARCH ARTICLE A CLINICAL STUDY OF DYSLIPIDEMIA IN PATIENTS OF CHRONIC KIDNEY DISEASE Gourav Garg 1, Sumit Pal Singh Chawla 2 * and Sarabjot Kaur 2 1 Department of Medicine, Government Medical
More informationThe effect of omega-3 on serum lipid profile in hemodialysis patients
J Renal Inj Prev. 2015; 4(3): 68-72. DOI: 10.12861/jrip.2015.14 Journal of Renal Injury Prevention The effect of omega-3 on serum lipid profile in hemodialysis patients Hamid Reza Omrani 1, Yahya Pasdar
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationA STUDY ON DYSLIPIDAEMIA IN CHRONIC KIDNEY DISEASE (CKD) WITH SPECIAL REFERENCE TO HAEMODIALYSIS
A STUDY ON DYSLIPIDAEMIA IN CHRONIC KIDNEY DISEASE (CKD) WITH SPECIAL REFERENCE TO HAEMODIALYSIS Shweta Sharma 1, Sandhya Gautam 2, Dhanveer Singh 3, Prachi Sharma 4, Avriti Baweja 5 1Assistant Professor,
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationGender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity
71 P.P.Bidzilya Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationNutrition, Food, and Fitness. Chapter 6 Fats: A Concentrated Energy Source
Nutrition, Food, and Fitness Chapter 6 Fats: A Concentrated Energy Source Tools: Printer (color optional) 4 sheets of 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationNutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source
Tools: Printer 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut along dashed lines Copyright Goodheart-Willcox Co., Inc. All rights reserved. Tissue in which the body
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationStudy of Lipid Profile in Patients with Chronic Kidney Disease on Conservative Management and Hemodialysis
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/22 Study of Lipid Profile in Patients with Chronic Kidney Disease on Conservative Management and Hemodialysis K Rajani
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationChronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza
Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management Fabio Mazza CKD (Chronic Kidney Disease) is an ever-increasing clinical condition marked by a progressive reduction
More informationKIDNEY DISEASE is associated with a number
PATIENT EDUCATION Column Editor: Beth McQuiston, MS, RD, LD Tips for Cholesterol Control in Patients on Hemodialysis Philippa Norton Feiertag, MEd, RD, CSR, LD Submitted by Philippa Norton Feiertag, MEd,
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationSupplemental table 1. Dietary sources of protein among 2441 men from the Kuopio Ischaemic Heart Disease Risk Factor Study MEAT DAIRY OTHER ANIMAL
ONLINE DATA SUPPLEMENT 1 SUPPLEMENTAL MATERIAL Pork Bacon Turkey Kidney Cream Cottage cheese Mutton and lamb Game (elk, reindeer) Supplemental table 1. Dietary sources of protein among 2441 men from the
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationThe role of physical training in lowering the cardio-metabolic risk
The role of physical training in lowering the cardio-metabolic risk Timea Szasz 1, Eugen Bota 2, Lucian Hoble 3 Abstract The cardio-metabolic risk represents the overall risk of developing type 2 diabetes
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationSmall dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study
Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More informationEFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS
EFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS Nora Vigasini, Assistant Professor, Department of Home Science, Women s Christian College, Chennai, noravigas@gmail.com
More informationChronic Kidney Disease with Special Reference to Dyslipidemia
IJHRMLP, Vol: 02 No: 02, July, 2016 Printed in India 2014 IJHRMLP, Assam, India ORIGINAL PAPER Chronic Kidney Disease with Special Reference to Dyslipidemia (Page 18-23) Chronic Kidney Disease with Special
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationDyslipidemia in chronic kidney disease excluding diabetic and nephrotic aetiology
International Journal of Advances in Medicine Velayudham R et al. Int J Adv Med. 2017 Dec;4(6):1586-1590 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175172
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationDietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components?
Dietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components? 3 rd International Conference of European Renal Nutrition Working Group of ERA-EDTA
More informationEicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationVitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients
In The Name of GOD Vitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients Authors & Affiliations: 1-jamal hallajzadeh; Maraghe University of
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationAspirin Resistance in Patients with Chronic Renal Failure (P 5325)
Aspirin Resistance in Patients with Chronic Renal Failure (P 5325) Beste Ozben Sadic 1, Azra Tanrikulu 1, Mehmet Koc 2, Tomris Ozben 3, Oguz Caymaz 1 1 Marmara University, Faculty of Medicine, Department
More informationApelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure CI Liakos, 1 EA Sanidas, 1 DN Perrea, 1 V Gennimata, 1 V Chantziara, 1 CA Grassos, 2 N-A Viniou, 1 JD Barbetseas,
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationThe health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences
The health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences What should we be promoting? Define health benefits in terms
More informationA comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus
Original Research Article A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Deepa Kalikavil Puthenveedu 1, Sundaraj
More informationSERUM LIPID PROFILES DURING ONSET AND REMISSION OF STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDREN: A PROSPECTIVE CASE CONTROL STUDY
Indian J.L.Sci. 5 (2) : 27-31, 2016 SERUM LIPID PROFILES DURING ONSET AND REMISSION OF STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDREN: A PROSPECTIVE CASE CONTROL STUDY a1 b c SRINIVASA MURTHY C L, RAHIMTAJ
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationAssociation between Pruritus and Serum Concentrations of Parathormone, Calcium and Phosphorus in Hemodialysis Patients
Saudi J Kidney Dis Transpl 2013;24(4):702-706 2013 Saudi Center for Organ Transplantation Original Article Saudi Journal of Kidney Diseases and Transplantation Association between Pruritus and Serum Concentrations
More information. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c
208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationReplacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins
Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins Muller H, Jordal O, et al. (998) Replacement of partially hydrogenated soybean
More informationBCH 447. Triglyceride Determination in Serum
BCH 447 Triglyceride Determination in Serum Introduction: Triglycerides are esters of fatty acids and are hydrolyzed by lipase to glycerol and free fatty acids. Triglyceride determinations when performed
More informationMacro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease. T. Alp Ikizler, MD Vanderbilt University Medical Center
Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease T. Alp Ikizler, MD Vanderbilt University Medical Center Nutrition and Chronic Kidney Disease What is the disease itself and
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationOmega-3 Fatty Acid Effect in Cardiovascular Disease Risk Factors
Volume 1, Issue no. 1, DOI 10.18502/ajne.v1i1.1220 Production and Hosting by Knowledge E Research Article Omega-3 Fatty Acid Effect in Cardiovascular Disease Risk Factors Alketbi Fatima Mohammed, Bolaji
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationNEWS & VIEWS. Hole in the diet-heart hypothesis?
NEWS & VIEWS Hole in the diet-heart hypothesis? Philip C. Calder Faculty of Medicine, University of Southampton, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom and
More informationPHYSICAL EXERCISES FOR DIABETIC POLYNEUROPATHY
STUDIA UBB EDUCATIO ARTIS GYMN., LIX, 4, 2014, pp. 101-106 (RECOMMENDED CITATION) PHYSICAL EXERCISES FOR DIABETIC POLYNEUROPATHY DOCU AXELERAD ANY 1*, DOCU AXELERAD DANIEL 2 ABSTRACT. Introduction: Chronic
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationAMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study
AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study HE Bays, 1 CM Ballantyne, 2 JJ Kastelein, 3 E Stein, 4 JL Isaacsohn,
More informationShaomei Yu-Poth, Guixiang Zhao, Terry Etherton, Mary Naglak, Satya Jonnalagadda, and Penny M Kris-Etherton. See corresponding editorial on page 581.
Effects of the National Cholesterol Education Program s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis 1,2 Shaomei Yu-Poth, Guixiang Zhao, Terry
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationAntagonistic Effects of Vitamin D and Parathyroid Hormone on Lipoprotein Lipase in Cultured Adipocytes
J Am Soc Nephrol 10: 2158 2164, 1999 Antagonistic Effects of Vitamin D and Parathyroid Hormone on Lipoprotein Lipase in Cultured Adipocytes UWE QUERFELD,* MICHAEL M. HOFFMANN, GÜNTER KLAUS, FRANK EIFINGER,*
More informationSupplementary Online Content
Supplementary Online Content Irish AB, Viecelli AK, Hawley CM, et al; for the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group.
More informationFacts on Fats. Ronald P. Mensink
Facts on Fats Ronald P. Mensink Department of Human Biology NUTRIM, School for Nutrition, Toxicology and Metabolism Maastricht University Maastricht The Netherlands Outline of the Presentation Saturated
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More information